Celldex Therapeutics (CLDX) Other Accumulated Expenses (2010 - 2026)

Celldex Therapeutics' Other Accumulated Expenses history runs 17 years deep, the most recent figure standing at $1.2 million for Q1 2026.

• On a quarterly basis, Other Accumulated Expenses fell 25.59% year-over-year to $1.2 million in Q1 2026; TTM through Mar 2026 was $1.2 million, a 25.59% decrease from a year earlier, with the FY2025 full-year figure at $1.2 million, up 30.57% from the prior year.
• Other Accumulated Expenses was little changed at $1.2 million in Q1 2026 per CLDX's latest filing, from $1.2 million in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $4.2 million in Q3 2023 and bottomed at $378000.0 in Q4 2023.
• The 5-year median for Other Accumulated Expenses is $1.2 million (2025), against an average of $1.7 million.
• Across the five-year window, Other Accumulated Expenses soared 296.42% in 2024 and tumbled 74.68% in 2025, its largest moves.
• Year by year, Other Accumulated Expenses stood at $990000.0 in 2022, then slumped by 61.82% to $378000.0 in 2023, then jumped by 149.21% to $942000.0 in 2024, then jumped by 30.57% to $1.2 million in 2025, then changed by 0.0% to $1.2 million in 2026.
• Per Business Quant, the three latest CLDX Other Accumulated Expenses figures stand at $1.2 million (Q1 2026), $1.2 million (Q4 2025), and $930000.0 (Q3 2025).